Amalgamated Bank
LYEL icon

Amalgamated Bank’s Lyell Immunopharma LYEL Stock Holding History

Amalgamated Bank’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-300
Closed -$3K – 3084
2025
Q1 		$3K Hold
300
– – ﹤0.01% 2790
2024
Q4 		$4K Hold
300
– – ﹤0.01% 2793
2024
Q3 		$8K Hold
300
– – ﹤0.01% 2558
2024
Q2 		$9K Hold
300
– – ﹤0.01% 2515
2024
Q1 		$13K Sell
300
-465
-61% -$19.9K ﹤0.01% 2325
2023
Q4 		$30K Sell
765
-89
-10% -$3.21K ﹤0.01% 2463
2023
Q3 		$25K Hold
854
– – ﹤0.01% 2547
2023
Q2 		$54K Sell
854
-41
-5% -$2.27K ﹤0.01% 2288
2023
Q1 		$42K Sell
895
-211
-19% -$11.3K ﹤0.01% 2369
2022
Q4 		$77K Hold
1,106
– – ﹤0.01% 2245
2022
Q3 		$162K Buy
1,106
+10
+0.9% +$1.35K ﹤0.01% 1931
2022
Q2 		$143K Sell
1,096
-2
-0.2% -$204 ﹤0.01% 2024
2022
Q1 		$111K Buy
+1,098
New +$133K ﹤0.01% 2156

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Amalgamated Bank's LYEL Position: Q2 2025 in Review

Amalgamated Bank sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 300 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in LYEL in Q1 2022 and held it in 13 quarters. The position peaked at $162K in Q3 2022. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Amalgamated Bank reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 300 Lyell Immunopharma shares in Q2 2025, an estimated $3K.
  • Amalgamated Bank first reported a position in Lyell Immunopharma in Q1 2022 and held it in 13 quarters.
  • Amalgamated Bank's Lyell Immunopharma position peaked at $162K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.